💰 Copay Assistance Program Impact Simulator

Specialty Tiers, Coinsurance, and the Cost-Sharing Cliff

Most commercial formularies place biologics, cell/gene therapies, and other high-cost specialty products on the top tier (Tier 4 or 5), where cost-sharing is structured as coinsurance — typically 25–40% of the drug's allowed amount — rather than a flat dollar copay. For a $8,200/month biologic, a 33% coinsurance rate produces a single pharmacy-counter charge of roughly $2,700, often due in full before the deductible is satisfied.

• 25–40%: Specialty tier coinsurance range (vs. $10–50 flat copay, generic tiers)
• $5,500+/mo: Median specialty drug price (IQVIA Institute, 2023 launch cohort)
• >45%: Abandonment at >$500 OOP (IQVIA claims analysis, first fill)
• $9,450: ACA individual OOP max (2024) (annual, all cost-sharing combined)

Coinsurance versus flat copay — why specialty tiers hurt more

Formulary tier design has shifted decisively toward coinsurance for specialty products since the early 2010s, driven by PBM benefit consultants seeking to shift financial risk to patients and manufacturers rather than plan sponsors:

Tier 1 (generic): flat copay, typically $5–15 Tier 2 (preferred brand): flat copay, typically $30–60 Tier 3 (non-preferred brand): flat copay or low coinsurance, $60–100 or 20% Tier 4/5 (specialty): coinsurance, 25–40% of allowed amount, frequently uncapped per-fill

Because coinsurance scales with list price, drugs with the highest launch prices generate the highest absolute patient liability — the opposite of risk protection. A patient facing 30% coinsurance on an $8,200 biologic owes $2,460 at a single fill, often within the first weeks of a plan year before any deductible credit has accumulated.

Employer-sponsored plans increasingly pair specialty tiers with a separate, higher specialty deductible ($250–1,000) that must be met before coinsurance even applies, compounding first-fill exposure.

Quantifying abandonment risk at the pharmacy counter

IQVIA Institute and Prime Therapeutics claims-based studies consistently show a dose-response relationship between out-of-pocket cost at first fill and primary non-adherence (the prescription is never picked up):

• OOP $0–50: abandonment ~6–10% • OOP $51–250: abandonment ~15–22% • OOP $251–500: abandonment ~28–35% • OOP >$500: abandonment ~45–60%

The relationship is not linear — each threshold represents a behavioral cliff where patients disengage from a prescriber-recommended therapy purely on affordability grounds, independent of clinical appropriateness. For chronic conditions (rheumatoid arthritis, MS, IBD) this "cost-related non-initiation" converts directly into avoidable disease progression and downstream utilization (ED visits, hospitalization) that frequently exceeds the drug's cost.

A 2022 Prime Therapeutics analysis of 35,000 new specialty starts found that patients with first-fill OOP above $250 were 2.7× more likely to abandon therapy within 30 days than those with OOP under $50 — establishing the "$250 abandonment threshold" now widely cited in payer benefit design discussions.

Manufacturer Copay Cards and the Patient Support Hub

To blunt abandonment at the specialty-tier cliff, manufacturers fund copay assistance ("copay card") programs, typically administered through third-party hub services such as AssistRx, PSKW/Lash Group, or TrialCard. These hubs verify insurance eligibility, run benefits investigations, and issue a virtual card carrying its own BIN/PCN/Group identifiers that the pharmacy adjudicates as a secondary payer.

• $15,000–25,000: Typical annual card maximum (per patient, per calendar year)
• 100%: Federal beneficiary exclusion (Medicare/Medicaid barred — Anti-Kickback Statute)
• <24–48 hrs: Hub enrollment turnaround (electronic benefits investigation)
• ~55–65%: Commercially-insured eligible pop. (of U.S. specialty drug users)

Why federal beneficiaries are excluded — the Anti-Kickback Statute

Manufacturer copay cards are legally restricted to patients with commercial (employer-sponsored, ACA marketplace, or individually purchased) insurance. Medicare Part D and Medicaid beneficiaries are categorically excluded because the federal Anti-Kickback Statute (42 U.S.C. §1320a-7b) treats direct manufacturer payment of a federal program beneficiary's cost-sharing as an inducement to purchase the manufacturer's product using federal funds — a form of remuneration the OIG has repeatedly flagged in Special Advisory Bulletins (most recently reaffirmed 2014, with enforcement guidance updated 2020–2023).

This creates the "copay assistance gap": Medicare Part D beneficiaries facing the same specialty-tier coinsurance as commercially insured patients cannot use manufacturer cards at all. Independent, non-manufacturer-affiliated charitable patient assistance programs (PAPs) — the HealthWell Foundation, the Patient Access Network (PAN) Foundation, the Patient Advocate Foundation, and disease-specific funds — exist specifically to serve this population, funded by manufacturer donations but operated at arm's length with no product-specific steering, which OIG guidance requires to avoid Anti-Kickback exposure.

The benefits investigation and hub enrollment workflow

A typical hub enrollment sequence, executed largely by specialty pharmacy or prescriber office staff on the patient's behalf:

1. Prescriber submits enrollment form (fax, ePA portal, or hub web intake) with ICD-10 diagnosis code, NPI, and insurance card details 2. Hub runs an electronic benefits investigation (EBI) against the payer's eligibility system (270/271 HIPAA transaction) to confirm active commercial coverage, plan type, and specialty pharmacy network requirements 3. Diagnosis is matched against the drug's FDA-approved label to confirm on-label use eligibility for card funding 4. Card is issued: a virtual BIN (Bank Identification Number)/PCN (Processor Control Number)/Group combination that routes as a distinct secondary payer in the pharmacy's claims-processing switch 5. Annual maximum benefit is set (commonly $15,000–25,000) and a running balance is tracked by the hub's claims-processing vendor in real time

Enrollment itself is typically free to the patient and completed within 24–48 hours for electronic benefits investigations, though complex prior-authorization-linked products can take longer.

NCPDP D.0 Dual Adjudication at the Pharmacy Counter

At the point of sale, the pharmacy system runs two sequential electronic claims using the NCPDP Telecommunication Standard D.0 — first to the primary payer (the health plan's PBM), then, using coordination-of-benefits (COB) segments, to the manufacturer copay card as a secondary payer. The card absorbs the patient's residual liability up to its per-fill and annual caps.

• NCPDP D.0: Claims standard (HIPAA-mandated pharmacy telecom format)
• <2 sec: Typical claim round-trip (real-time switch adjudication)
• $0–25: Common patient co-pay floor (after card applies, per fill)
• $2,000–3,000: Per-fill card cap (typical) (varies by manufacturer program)

How coordination-of-benefits routing works at the switch

The pharmacy dispensing system transmits claims through a claims-processing switch (RelayHealth, Change Healthcare, etc.) that routes to whichever BIN/PCN the pharmacist enters:

Primary claim (health plan): NCPDP D.0 B1 (billing) transaction includes drug NDC, days supply, and pricing segment; PBM adjudicates against the benefit design and returns the plan-paid amount plus patient responsibility (deductible/coinsurance/copay owed field, NCPDP field 505-F5).

Secondary/COB claim (copay card): a second B1 transaction is submitted with the "other payer amount paid" (NCPDP 431-DV) and "other payer-patient responsibility amount" (352-NQ) fields populated from the primary response. The card processor's system then adjudicates against the remaining patient responsibility, applying its own per-fill maximum and decrementing the patient's running annual card balance.

The pharmacist sees a final adjudicated patient-pay amount reflecting both transactions — commonly reduced from several thousand dollars to a $0–25 counter payment — within the same two-to-three second real-time transaction window as the primary claim.

The 2012 shift to NCPDP D.0 (replacing version 5.1) was itself an ANSI/HIPAA-mandated standard specifically because it added structured COB fields robust enough to support exactly this kind of dual-payer secondary claim — copay card adjudication as it exists today would not function reliably on the older standard.

What actually happens to the manufacturer's dollars downstream

The critical, non-obvious fact in copay assistance economics is this: the dollars the manufacturer pays at the point of sale are accepted by the pharmacy and by the health plan's claims system as valid payment toward the total claim cost. From the pharmacy's perspective, the claim is fully paid. What the health plan's PBM does internally with the accounting of "who paid what" — specifically, whether the manufacturer-paid portion is credited toward the patient's deductible and out-of-pocket maximum accrual, or excluded from it — is a separate, largely invisible-to-the-patient policy decision made downstream in the plan's benefit administration system. This is precisely the mechanism that accumulator adjustment programs (Stage 4) exploit.

Copay Accumulator and Maximizer Programs — Redirecting the Benefit

A copay accumulator adjustment program (AAP), operated by the PBM or a specialized vendor (SaveOnSP, PillarRx, and similar), tracks manufacturer copay card payments separately and excludes them from counting toward the patient's deductible and annual out-of-pocket maximum — even though the pharmacy already accepted those dollars as payment. When the card's annual cap is exhausted, the patient is suddenly liable for the full, unmet coinsurance with no accumulated progress toward their OOP max.

• ~40–50%: Plans with an AAP (2024) (of commercial plans, Avalere/AIS tracking)
• 20+ + PR: States banning accumulators (fully-insured plans only; ERISA exempt)
• Month 5–7: Median month of card exhaustion (when AAP is active vs. month 11–12 without)
• $2,000–3,500: Post-exhaustion monthly liability (full coinsurance resumes abruptly)

Accumulator versus maximizer — two distinct mechanisms

Two related but mechanically distinct vendor programs operate in this space:

Copay Accumulator Adjustment Programs (AAPs): the manufacturer's payment is applied at the pharmacy counter as before, but the PBM's benefit-tracking system does NOT credit that dollar amount toward the patient's deductible or OOP maximum. The patient's "true" accumulator (the internal running total the plan uses to determine when cost-sharing obligations end for the year) stalls near zero even as thousands of dollars are being paid on their behalf. When the manufacturer card's annual cap (commonly $15,000–25,000) is exhausted — often mid-year, because the full coinsurance amount is being drawn down each month rather than just the smaller "true" patient share — the patient is abruptly responsible for the full, un-accrued coinsurance.

Copay Maximizer Programs: a subtler variant that runs proactively from January 1. The vendor calculates the copay card's total annual maximum and divides it evenly across 12 months, then sets the patient's monthly "copay" obligation at exactly that amount — maximizing the total dollars extracted from the manufacturer program over the full plan year, while, as with accumulators, none of it counts toward the deductible/OOP max. Maximizers are marketed to plan sponsors as reducing plan spend without exhausting the card early.

The regulatory patchwork — state bans, ERISA preemption, and CMS rulemaking

Because health insurance in the U.S. is regulated at both state and federal levels, accumulator programs face a fragmented legal landscape:

• State-level bans: as of 2024, more than 20 states plus Puerto Rico (including Arizona, Illinois, Virginia, West Virginia, Georgia, and Louisiana) have enacted laws requiring insurers to count manufacturer copay assistance toward the patient's deductible and OOP maximum for fully-insured plans regulated at the state level.

• ERISA preemption gap: self-funded employer plans (covering roughly 65% of commercially insured Americans) are regulated under ERISA, a federal law that preempts state insurance mandates. State accumulator bans therefore do NOT apply to the majority of large-employer plans, leaving most commercially insured patients unprotected regardless of which state they live in.

• Federal rulemaking whiplash: CMS's 2020 Notice of Benefit and Payment Parameters permitted accumulator adjustment whenever a medically appropriate generic equivalent existed. A 2021 rule attempted to require crediting of copay assistance broadly. Litigation (HIV+Hepatitis Policy Institute v. HHS, D.D.C. 2023) found the government's 2021 position inconsistently applied, remanding the rule and leaving the accumulator legality question unsettled at the federal level as of the current plan year — with the "All Copays Count Act" repeatedly introduced in Congress but not yet enacted.

A 2023 HealthWell Foundation / Avalere analysis found that patients enrolled in plans with active accumulator adjustment programs discontinued therapy at a rate 2.5–3× higher than patients whose manufacturer assistance counted toward their OOP maximum — with the sharpest drop-off occurring in the specific month the copay card's annual balance was exhausted.

Adherence, Persistence, and the Net Cost-Shift Ledger

Twelve-month pharmacy claims data reveal the downstream consequence of accumulator adjustment: proportion-of-days-covered (PDC), the standard PBM/CMS adherence metric, diverges sharply between patients in accumulator-adjusted plans and those whose manufacturer assistance counted normally, with the gap widening precisely around the month the manufacturer card is exhausted.

• ~61%: PDC, accumulator-adjusted cohort (well below 80% adherence threshold)
• ~87%: PDC, non-adjusted cohort (card savings sustained all plan year)
• ~38%: 12-month discontinuation, AAP (vs. ~9% without accumulator adjustment)
• 5–15%: Plan-sponsor net savings claim (of specialty spend — contested by ICER)

Proportion of Days Covered (PDC) as the adherence yardstick

PDC — the CMS Star Ratings and PQA-endorsed standard adherence metric — measures the percentage of days in a defined period a patient has drug on hand, based on fill dates and days-supply fields in pharmacy claims:

PDC = (days covered by fills) / (days in measurement period)

A PDC ≥80% is the conventional clinical threshold associated with meaningful reduction in disease progression and downstream utilization for chronic conditions. Cohort studies comparing accumulator-adjusted versus non-adjusted patient populations on the same specialty biologic consistently show:

• Non-adjusted cohort: PDC often 85–90%, driven by consistently low $0–25 monthly out-of-pocket cost sustained across the full plan year • Accumulator-adjusted cohort: PDC frequently falls to 55–65%, tracking a bimodal pattern — near-perfect adherence in months 1 through card-exhaustion (5–7), followed by a sharp cliff once full coinsurance resumes

The divergence is not attributable to clinical or demographic differences between cohorts (matched-cohort designs control for these) — it is a direct behavioral response to the sudden cost-sharing shock at card exhaustion.

The contested net cost-shift — who actually pays less

PBMs and plan sponsors that adopt accumulator programs argue they reduce overall plan drug spend by capturing manufacturer dollars that would otherwise substitute for plan payment — the "we shouldn't subsidize brand-name drugs when generics exist" rationale, plus a genuine claim of extracting maximum value from a fixed manufacturer benefit pool.

Patient advocacy organizations, ICER (Institute for Clinical and Economic Review), and multiple state legislatures counter that the true cost shift lands on patients least able to absorb it — those with chronic, high-severity conditions requiring specialty biologics — and that resulting non-adherence generates offsetting downstream medical costs (hospitalization, disease flares, ED utilization) that are frequently absorbed by the same plan sponsor, partially or fully offsetting the pharmacy-line "savings."

A 2022 Milliman actuarial analysis modeling a mid-size self-funded employer plan estimated that avoidable medical costs from accumulator-driven non-adherence offset 30–60% of the claimed pharmacy benefit savings within 18 months, though results vary widely by therapeutic category and are difficult to isolate cleanly from other cost trends — making the accumulator "savings" claim one of the more actively litigated empirical questions in current pharmacy benefit design.

The Federal Employees Health Benefits (FEHB) Program prohibited copay accumulator adjustment programs across all its plans starting plan year 2023 — one of the largest single purchasers in the country (covering ~8 million lives) choosing to require crediting of manufacturer assistance, a frequently cited precedent in ongoing state and federal accumulator-ban advocacy.